|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
1999-2-2
|
|
pubmed:abstractText |
Starting from a series of 2-aminotetralins 1, a novel series of N-[4-(4-phenylbenzoylamino)butyl]-octahydrobenzoquinolines and hexahydrobenzoindoles with high potency and selectivity for the dopamine D3 receptor has been designed. The effect of ligand chirality on binding affinity has been established. Selected derivatives (e.g. 2o, 2p) show high functional selectivity and enhanced in vivo properties compared to 1.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:AvenellK YKY,
pubmed-author:BoyfieldII,
pubmed-author:ColdwellM CMC,
pubmed-author:HadleyM SMS,
pubmed-author:HealyM AMA,
pubmed-author:JeffreyP MPM,
pubmed-author:JohnsonC NCN,
pubmed-author:NashD JDJ,
pubmed-author:RileyG JGJ,
pubmed-author:ScottE EEE,
pubmed-author:SmithS ASA,
pubmed-author:StaceyRR,
pubmed-author:StempGG,
pubmed-author:ThewlisK MKM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2859-64
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Fused aminotetralins: novel antagonists with high selectivity for the dopamine D3 receptor.
|
|
pubmed:affiliation |
SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, UK.
|
|
pubmed:publicationType |
Journal Article
|
